Spots Global Cancer Trial Database for check point inhibitor
Every month we try and update this database with for check point inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | NCT03755440 | Gastric Cancer ... EBV | PD-1 antibody (... | 18 Years - | Sun Yat-sen University | |
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | NCT03755440 | Gastric Cancer ... EBV | PD-1 antibody (... | 18 Years - | Sun Yat-sen University | |
| Durvalumab in Pediatric and Adolescent Patients | NCT02793466 | Solid Tumor Lymphoma Central Nervous... | Durvalumab; MED... | 1 Year - 17 Years | Children's Hospital Los Angeles | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | NCT05047094 | Head and Neck S... Skin Cancer Metastatic Head... | Diffusing Alpha... Pembrolizumab | 18 Years - | Alpha Tau Medical LTD. | |
| Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer | NCT03532737 | Locally Advance... | Pembrolizumab | 16 Years - | Kuwait Cancer Control Center | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study | NCT06095674 | Cervical Cancer | Anti-PD-1 antib... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | NCT04137900 | Advanced Unrese... Metastatic Soli... | TAB004 Toripalimab | 18 Years - | TopAlliance Biosciences | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | NCT02836834 | Lymphoma Lung Cancer | JS001 | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
